Cansino Biologics Inc (688185)

Currency in CNY
85.40
-3.08(-3.48%)
Delayed Data·
688185 Scorecard
Full Analysis
Net income is expected to grow this year
688185 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
84.7388.75
52 wk Range
37.1292.70
Key Statistics
Bid/Ask
85.40 / 85.58
Prev. Close
88.48
Open
87.3
Day's Range
84.73-88.75
52 wk Range
37.12-92.7
Volume
3.77M
Average Volume (3m)
2.28M
1-Year Change
115.51%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688185 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
70.48
Downside
-17.47%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Cansino Biologics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Cansino Biologics Inc Company Profile

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.

Employees
1105
Market
China

Compare 688185 to Peers and Sector

Metrics to compare
688185
Peers
Sector
Relationship
P/E Ratio
−74.6x−16.5x−0.5x
PEG Ratio
−0.820.290.00
Price/Book
3.4x6.5x2.6x
Price / LTM Sales
18.9x23.5x3.3x
Upside (Analyst Target)
−14.0%0.6%43.5%
Fair Value Upside
Unlock−8.2%6.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 70.48
(-17.47% Downside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.05 / --
Revenue / Forecast
137.16M / --
EPS Revisions
Last 90 days

688185 Income Statement

FAQ

What Stock Exchange Does Cansino Biologics Trade On?

Cansino Biologics is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for Cansino Biologics?

The stock symbol for Cansino Biologics is "688185."

What Is the Cansino Biologics Market Cap?

As of today, Cansino Biologics market cap is 16.44B.

What Is Cansino Biologics's Earnings Per Share (TTM)?

The Cansino Biologics EPS (TTM) is -0.90.

When Is the Next Cansino Biologics Earnings Date?

Cansino Biologics will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is 688185 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cansino Biologics Stock Split?

Cansino Biologics has split 0 times.

How Many Employees Does Cansino Biologics Have?

Cansino Biologics has 1105 employees.

What is the current trading status of Cansino Biologics (688185)?

As of 07 Aug 2025, Cansino Biologics (688185) is trading at a price of 85.40, with a previous close of 88.48. The stock has fluctuated within a day range of 84.73 to 88.75, while its 52-week range spans from 37.12 to 92.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.